Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort
- 1 March 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 203 (3), 505-511
- https://doi.org/10.1097/ju.0000000000000593
Abstract
Purpose: To apply non-muscle invasive bladder cancer (NMIBC) AUA/SUO guidelines for risk-stratification and analyze predictors of recurrence and progression. Methods: Retrospective review of 398 patients with NMIBC treated between 2001 and 2017. Descriptive statistics were used to compare AUA/SUO risk-groups. Predictors of recurrence and progression were determined by multivariable regression. Kaplan Meier analysis, Cox proportional hazards regression model and time-dependent AUC was performed to determine progression-free and recurrence-free survival by risk-group. Results: Median follow-up was 37-months (95% CI: 35- to 42-months). 92% of patients underwent BCG induction and 46% of patients received at least 1 course of maintenance treatment. There were 11.5% low-risk, 32.5% intermediate-risk and 55.8% high-risk patients. The 5-year progression-free survival (PFS) and recurrence-free survival (RFS) for low-, intermediate- and high-risk patients was 93%, 74% and 54% and 43%, 33% and 23%, respectively. On Kaplan Meier analysis, HG Ta ≤3cm RFS and PFS stratified between intermediate and high-risk group. Relative to low-risk, classification as intermediate- or high-risk was an independent predictor of progression (HR: 9.7, CI: 2.23–42.0, p<0.01 and HR: 36, CI: 8.16–159, p<0.001, respectively). High-risk patients were more likely to recur relative to low-risk patients (HR: 2.03, CI: 1.11–3.71, p=0.022). For recurrence and progression, 1 year AUC values were 0.60 (CI: 0.546–0.656) and 0.68 (CI: 0.622–0.732), respectively. Conclusions: The AUA/SUO NMIBC risk-classification system appropriately stratifies patients based on likelihood of recurrence and progression and should be used at the time of diagnosis to counsel patients and guide therapy.Keywords
This publication has 12 references indexed in Scilit:
- Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC)World Journal of Urology, 2018
- Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non–muscle-invasive Bladder CancerEuropean Urology Focus, 2018
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder TumoursEuropean Urology, 2016
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016European Urology, 2016
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO GuidelineJournal of Urology, 2016
- EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-GuérinEuropean Urology, 2016
- Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder CancerJournal of Urology, 2014
- The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk TablesEuropean Urology, 2011
- External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancerWorld Journal of Urology, 2010
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006